{"title":"Evidencias del sacubitrilo-valsartán en pacientes con diagnóstico reciente de insuficiencia cardiaca","authors":"Manuel Martínez-Sellés","doi":"10.1016/S1131-3587(20)30002-9","DOIUrl":null,"url":null,"abstract":"<div><p>New data confirm the usefulness of sacubitril–valsartan in patients with de novo heart failure (HF) with a reduced left ventricular ejection fraction. Most of these patients do not receive regular treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor blockers (ARBs). Although fewer data are available on the usefulness of sacubitril–valsartan in patients with de novo HF than in those with chronic HF, more is known about its use in patients with de novo HF than about the use of other HF drugs, such as ACE inhibitors and ARBs, in these patients. In fact, recent reports support giving sacubitril–valsartan to patients with de novo HF, particularly to those admitted to hospital. Sacubitril–valsartan has similar benefits to enalapril in both patients with de novo HF and those with a history of HF. Consequently, the initial hospital admission for HF with a reduced ejection fraction is a good time to start sacubitril–valsartan. Although information on the use of neprilysin inhibitors in ambulatory patients with de novo HF is scarcer, the data suggest these drugs could also be started in this setting.</p></div>","PeriodicalId":34926,"journal":{"name":"Revista Espanola de Cardiologia Suplementos","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Cardiologia Suplementos","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1131358720300029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
New data confirm the usefulness of sacubitril–valsartan in patients with de novo heart failure (HF) with a reduced left ventricular ejection fraction. Most of these patients do not receive regular treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor blockers (ARBs). Although fewer data are available on the usefulness of sacubitril–valsartan in patients with de novo HF than in those with chronic HF, more is known about its use in patients with de novo HF than about the use of other HF drugs, such as ACE inhibitors and ARBs, in these patients. In fact, recent reports support giving sacubitril–valsartan to patients with de novo HF, particularly to those admitted to hospital. Sacubitril–valsartan has similar benefits to enalapril in both patients with de novo HF and those with a history of HF. Consequently, the initial hospital admission for HF with a reduced ejection fraction is a good time to start sacubitril–valsartan. Although information on the use of neprilysin inhibitors in ambulatory patients with de novo HF is scarcer, the data suggest these drugs could also be started in this setting.
期刊介绍:
Revista Española de Cardiología, is an international scientific journal dealing with cardiovascular medicine. Revista Española de Cardiología, the official publication of the Spanish Society of Cardiology, publishes research articles related to cardiovascular diseases. Articles are published in Spanish for the paper edition and in both Spanish and English in the electronic edition, which is available on the Internet. Regular sections include original articles reporting clinical or basic research, brief reports, review articles, editorials and letters to the Editor.